Disruption of normal circadian rhythm physiology is associated with neurodegenerative disease, which can lead to symptoms such as altered sleep cycles. In Alzheimer's disease (AD), circadian dysfunction has been attributed to β-amyloidosis. However, it is unclear whether tauopathy, another AD-associated neuropathology, can disrupt the circadian clock. We have evaluated the status of the circadian clock in a mouse model of tauopathy (Tg4510). Tg4510 mice display a long free-running period at an age when tauopathy is present, and show evidence of tauopathy in the suprachiasmatic nucleus (SCN) of the hypothalamus -the site of the master circadian clock. Additionally, cyclic expression of the core clock protein PER2 is disrupted in the hypothalamus of Tg4510 mice. Finally, disruption of the cyclic expression of PER2 and BMAL1, another core circadian clock protein, is evident in the Tg4510 hippocampus. These results demonstrate that tauopathy disrupts normal circadian clock function both at the behavioral and molecular levels, which may be attributed to the tauopathy-induced neuropathology in the SCN. Furthermore, these results establish the Tg4510 mouse line as a model to study how tauopathy disrupts normal circadian rhythm biology.
Introduction
The circadian clock is an endogenous system designed to control the timing of numerous biological events so that an organism can anticipate and adapt to daily changes in the environment. In mammals, the master circadian clock is located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Housed in the neurons of the SCN, and in virtually every nucleated cell in the human body, is a molecular clock that controls the daily cyclic expression of clock-controlled genes through a transcriptional/translational negative feedback loop. At the core of this loop are the positive arm BMAL1 and CLOCK transcription factors that drive the expression of the Period (Per) and Cryptochrome (Cry) gene families, which then ultimately feedback to repress their own transcription (Ko and Takahashi, 2006; Partch et al., 2014) . This mechanism functions to maintain the timing of rhythmic output to about a 24 h period. A common biological process associated with circadian control is the sleep/wake cycle, which when disrupted (e.g. jet lag or shift work) can lead to or exacerbate many diseases and disorders such as cancer and diabetes (Sahar and Sassone-Corsi, 2009; Bass and Takahashi, 2010) . Additionally, circadian rhythm disruption has been associated with numerous neurodegenerative diseases, such as Alzheimer's disease (AD). In AD, circadian disruption manifests in disrupted sleep cycles, altered body temperature rhythms, and sundowning, which is an increase in the symptoms of dementia in the early evening hours (Scarmeas et al., 2007) . Furthermore, disruption of the clock most likely contributes to the severity of other symptoms associated with AD, such as memory loss, as normal circadian clock function is important to sustain learning and memory (Gerstner and Yin, 2010) .
Two of the central pathophysiological changes associated with Alzheimer's disease (AD) are β-amyloidosis, the formation of extracellular amyloid plaques due to the accumulation of the protein amyloid beta 42 (Aβ), and tauopathy, the formation of intracellular neurofibrillary tangles (NFTs) due to the aberrant accumulation and premature phosphorylation of tau protein, leading to a hyperphosphorylated isoform (Ittner and Gotz, 2011) . Numerous studies have shown a connection between circadian disruption and mouse models of β-amyloidosis. For example, the APP/PS1 double transgenic mouse line, a model of β-amyloidosis that begins to show Aβ plaque formation by 6-9 months of age (Radde et al., 2006) , has a 2 h phase delay in wakefulness (Duncan et al., 2012) . This is consistent with the CRSD observed in AD patients and suggests a defect in circadian regulation of sleep/wake patterns. APP transgenic mice, expressing only the human APP allele, have a long free-running period (the innate circadian rhythm in the absence of external cues such as light) in constant darkness (DD) as early as 5 months of age, which confirms that their endogenous circadian clock is dysfunctional when β-amyloidosis is evident (Wisor et al., 2005) . Interestingly, it has been shown that the soluble form of Aβ oscillates with the sleep/wake rhythm in APP/PS1 mice. However, this oscillation is lost in the early stages of β-amyloidosis in this model (Roh et al., 2012) , suggesting sleep/wake cycle disturbances may be an early indicator of β-amyloidosis. More recent work has demonstrated that Aβ can induce the degradation of BMAL1 and CREB binding protein (CBP) in yet another model of β-amyloidosis, the 5xFAD transgenic mouse line, providing a molecular mechanism for the Aβ-induced circadian disruption (Song et al., 2015) .
In contrast to β-amyloidosis, very few studies have assessed the contribution of tauopathy to circadian rhythm disruption. As previously mentioned, tauopathy is characterized by the aberrant phosphorylation and subsequent aggregation of the microtubule associated protein tau, and is evident in numerous neurodegenerative diseases such as frontotemporal dementia (FTD) and Alzheimer's disease (AD) (Rizzo et al., 2008) . Sleep disturbance is frequently comorbid with tauopathy, yet the etiology is poorly understood. For example, individuals suffering from FTD show disrupted sleep cycles that are indicative of a circadian rhythm sleep disorder (CRSD) ). This suggests a disruption of the circadian clock in individuals suffering from this neurodegenerative disease, yet to date the cause is unknown. Tauopathy is also present in the brains of individuals afflicted with AD and, as in FTD, disruption of the circadian clock is evident (Hastings and Goedert, 2013) . Although tauopathy manifests in the SCN of patients with AD, it is unknown how or if this impacts the molecular clock (Stopa et al., 1999) . Additionally, Sterniczuk et al. showed that the circadian clock is disrupted in a triple transgenic mouse line that expresses both tauopathy and β-amyloidosis (Sterniczuk et al., 2010) . However, this study did not identify how tauopathy specifically contributes to the observed clock defects as β-amyloidosis is also present. More recently, it has been shown that disruption of Doubletime, a kinase involved in regulating the timing of the circadian clock, leads to disruption of normal circadian function and to neurodegeneration indicative of tauopathy in the fruit fly Drosophila melanogaster (Means et al., 2015) . However, it is unknown whether this connection exists in mammals.
The work presented here is focused on addressing the current gap in our understanding of how tauopathy impacts normal circadian function in a mouse model of tauopathy, the Tg4510 transgenic mouse line. These mice develop progressive tau pathology starting at 2.5 months of age, leading to formation of NFTs, neuronal loss and brain atrophy by 6 months of age Dickey et al., 2009) . Our results demonstrate a long free-running period in transgenic Tg4510 mice at an age when tauopathy is evident, which indicates a disruption in the homeostatic timing of the master clock. Next, we show a disruption in the cyclic expression of the core clock protein PER2 in the hypothalamus, which indicates that tauopathy impacts the circadian clock at the molecular level. Furthermore, we show evidence of tauopathy in the SCN, which likely contributes to this disruption. Additionally, we demonstrate a disruption in the cyclic expression of PER2 and BMAL1 in the Tg4510 mouse hippocampus, an area important for normal learning and memory function. Taken together, our results demonstrate that normal circadian function is disrupted in a mouse model of tauopathy in regions of the brain important for sleep-timing and memory function.
Methods

Transgenic mice
Briefly, Tg410 mice were bred as heterozygotes for the Tet and P301L alleles to produce double transgenics (P301L and TET alleles), TET allele, or neither. For all studies described herein, non-transgenic littermates (no P301L or TET) with a background of FVB/129S were used as controls. All animal testing procedures and care followed the NIH guidelines and were approved by the University of South Florida's Institutional Animal Care and Use Committee (Approval ID number A4100-01).
Locomotor assessment of circadian activity
Throughout the experiment, male and female mice were individually housed with ad libitum access to food and water. Prior to the start of the experiment, mice were maintained on a 12-hour light/dark (LD) cycle. Mice were then moved to running wheel cages (Lafayette Instrument, Lafayette, IN) in light-tight, sound-attenuated cabinets. Activity, measured by revolutions of the running wheel, was recorded in 5 min bins using Scurry Activity Monitoring Software (Lafayette Instrument, Lafayette, IN). To assess free running period in the mice, the lights were turned off at ZT0 on day 12 and the mice were subjected to a 24-hour dark cycle (DD) for twelve days. Wheel activity was analyzed using ClockLab Analysis software (ClockLab, Actimetrics, Wilmette, IL). Activity was quantified as the number of wheel revolutions per minute occurring during 5-min bins. Average activity was calculated using the batch analysis in ClockLab software. The free-running period (τ) and amplitude were determined by chi-squared (χ 2 ) periodogram analysis. Activity bout analyses were exported using the "bout" function in ClockLab, with a bout defined as a period were the activity never fell below 5 counts/min for longer than 5 min. The length of the active period (α) was measured as the time between onset and offset of activity.
Tissue preparation for Western blot analysis
After the evaluation of free-running period in DD, mice were reentrained to a 12:12 LD cycle for 1 week and then released back into DD for 48 h prior to euthanasia. Mice were euthanized by cervical dislocation and rapid decapitation at two 12 h time points that corresponded to CT4 and CT16 for the non-transgenic mice, and CT6 and CT18 for the Tg4510s. CT was calculated using the formula: CT12 Day B = CT12 Day A + τ − 24 h (Jud et al., 2005) . Euthanasia was performed in the dark using night-vision goggles to avoid eliciting a light zeitgeber. Brains were harvested and the entire hypothalamus and hippocampus were completely removed before being flash frozen for further processing.
Tissue collection for histopathology
In a separate experiment to examine tau histopathology in the SCN, a cohort of 13 month-old transgenic mice and age-matched non-transgenic littermates were euthanized with a solution containing pentobarbital and phenytoin, then transcardially perfused with 25 ml of 0.9% normal saline solution. Mice were placed on an isothermal pad during perfusion to minimize generation of artifactual tau phosphorylation, which has been reported to result from lowered body temperature caused by the euthanizing solution (Planel et al., 2007; Maurin et al., 2014) . Brains were collected immediately following perfusion and fixed in 4% phosphate-buffered paraformaldehyde for 24 h and then cryoprotected in successive incubations of 10%, 20% and 30% sucrose solutions for 24 h each. Next, brains were frozen and sectioned on a sliding microtome in the coronal plane (25 μm thickness) and stored at 4°C in Dulbecco's phosphate buffered saline (PBS) with 10 mM sodium azide solution.
Histopathology
Stereological principles were employed to select the sections stained for each marker. Immunohistochemical procedural methods have been described previously (Gordon et al., 2002) . Sections from all animals were placed in a multi-sample staining tray and endogenous peroxidase was blocked (10% methanol, 3% H 2 O 2 in phosphate buffered saline, 10 mM NaPO 4 , 154 NaCl, pH 7.4, PBS; 30 min). Tissue samples were permeabilized with 0.2% lysine, 1%Triton X-100 in PBS solution and incubated overnight with antibodies targeting either in tau phosphorylated at Ser396 (rabbit polyclonal, Anaspec) or total tau H150 (rabbit polyclonal, SantaCruz Biotechnology). Sections were washed in PBS, and then incubated in corresponding biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) for 2 h and incubated with Vectastain® Elite® ABC kit (Vector Laboratories, Burlingame, CA) for enzyme conjugation. Finally, sections were stained using 0.05% diaminobenzidine, 0.5% nickel ammonium sulfate and 0.03% H2O2. Tissue sections were mounted onto slides, and counterstained with methyl green solution. Sections were rinsed with distilled water, and stained in methyl green solution 0.5% un 0.1 M sodium acetate buffer for 5 min. Slides were then rinsed in water, quickly dehydrated through 95% and 100% ethanol, cleared in xylene and cover slipped. Sections scanned using slide scanner Axio Scan Z.1 (Zeiss Inc.).
Western blot analysis
Brain tissue was lysed in Mammalian Protein Extraction Reagent (M-PER) with phosphatase and protease inhibitors (10 μl/ml, Halt™ Protease and Phosphatase Inhibitor Cocktail, Thermo Scientific Inc., Rockford, IL, USA) using sonication, left to incubate on ice for 10 min and centrifuged at 20,000g at 4°C for 20 min. The supernatant was taken, and centrifuged at 9000g at 4°C for 5 min. Supernatant was taken again and used for further analysis. Protein concentrations were determined using a BCA assay kit (Thermo scientific). Equal amounts of protein from brain lysate (30 μg) were resolved using 9.5% Tris-glycine polyacrylamide gels under reducing conditions. Proteins were transferred to nitrocellulose membranes (Bio-rad, Hercules CA), and blocked for 1 h at room temperature in blocking buffer which was a 5% non-fat milk (Labscientific, Inc., Livingston, NJ) and tris buffered saline containing 0.1% tween-20 solution (Boston Bioproducts, Ashland, MA). Membranes were then incubated overnight at 4°C with antibodies against target proteins, washed 3 × 10 min in tris buffered saline with 0.1% tween20 (TBS-T) then placed in blocking buffer combined with HRP-conjugated secondary antibody diluted 1:7500 and left to incubate at room temperature for 1 h. After thorough washing with TBS-T, bands were visualized using enhanced chemiluminescence (ECL; Thermo scientific) with an image analyzer (Amersham imager 600). Densitometry was performed using imageJ. Bands of the protein of interest were normalized to an endogenous protein loading control, beta-actin.
Reagents and antibodies
The following antibodies were used for immunodetection: anti-BMAL1 at 1:1000 (Bethyl Laboratories Inc., Montgomery, TX), anti-PER2 at 1:250 (ThermoFisher Scientific, Rockford, IL), anti-phosphotau (pSer 199/202 ) at 1:1000, (Anaspec, Fremont, CA), anti-phospho-tau (pSer 396 ) at 1:1000, (Anaspec, Fremont, CA), anti-B-Actin at 1:7500 (Sigma-Aldrich, St Louis, MO). For anti-B-actin, HRP conjugated goat anti-mouse (Southern Biotech, Birmingham, AL) was used. For all other antibodies, HRP conjugated goat anti-rabbit (Southern Biotech, Birmingham, AL) was used.
Statistical analysis
For statistical analysis, a Student independent samples t-test or twoway ANOVA was performed (using genotype and time of euthanasia), followed by Tukey post hoc tests. (*p b 0.05, **p b 0.01, ***p b 0.001) using Daniel's XL Toolbox add-in for Excel, version 6.70, by Daniel Kraus, Würzburg, Germany, and SPSS version 21.
Results
Tg4510 display a long free-running period mice at 8 months of age
We have assessed the free-running period of locomotor activity in the Tg4510 line, a mouse model of tauopathy, to determine if tauopathy can disrupt the normal homeostatic timing of the activity cycle as controlled by the master clock in the SCN. The Tg4510 double transgenic line is a TET-off transgenic mouse model of tauopathy that carries the human mutant P301L allele of tau (MAPT) where the TET transactivator is driven by a promoter (calcium/calmodulin kinase II; CaMKII) that promotes expression of the mutant tau allele in regions of the brain responsible for learning and memory (e.g. hippocampus, forebrain). This mouse line begins to show signs of tauopathy (pre-NFT formation) in these regions as early as 2.5 months of age . We evaluated free-running period at 8 months of age -an age when tauopathy is evident in this mouse line. Fig. 1A shows representative actograms from two mice of each genotype. Our results show transgenic (Tg) Tg4510 mice display a longer period free-running period in DD in comparison to non-transgenic (Ntg) controls [t(14) = 32.40, p b 0.001, Fig. 1B] , which indicates that the master circadian clock is disrupted during the later stages of tauopathy-induced pathology.
In addition to the long free-running period, we observed that the Tg4510 mice were more active during the light cycle in 12:12 LD than the Ntg controls, while there was no difference during the dark cycle [t(14) = 14.37, p b 0.05; Fig. 1B ]. Additionally the overall percentage of activity in the light cycle was higher for the Tg4510 mice [t(14) = 6.44, p b 0.05; Table 1 ], and the alpha phase, the phase of the circadian cycle when animals are active, was significantly longer for the Tg4510 mice than the non-transgenic controls in both LD and DD [t(14) = 9.78, p b 0.05 for LD; t(14) = 13.40, p b 0.01 for DD; Table 1 ]. However, no other circadian parameters measured, such as bouts of activity during the light phase, were significant (Table 1) .
Disruption of the molecular circadian clock in the hypothalamus of Tg4510 mice
The long free-running period indicates that the molecular clock located in the SCN is disrupted. To confirm this, we evaluated the status of the molecular clock in the hypothalamus, the location of the SCN, of free-running 8 month old Tg and Ntg mice by measuring the circadian oscillation patterns of the core clock proteins BMAL1 (positive arm) and PER2 (negative arm) (Fig. 2) . Dissections were performed at 2 time points that approximate the subjective morning (CT4-CT6) and evening (CT16-18). These times were chosen as they roughly correspond to the trough and peak of PER2 in the SCN under free-running conditions (Field et al., 2000) . Using a two-way ANOVA, there was no effect of time of day or genotype, and no interaction, on hypothalamic BMAL1 levels. However, there was an effect of time of day [F(1,14) = 5.48, p b 0.05), genotype (F(1,14) = 45.88, p b 0.001], and an interaction [F(1,11) = 9.23, p b 0.05] on hypothalamic PER2 levels. As expected, the Ntg mice show a significant increase in PER2 levels between during the subjective evening (p b 0.05), whereas the Tg mice show no increase in PER2. Our results show a disruption of the PER2 levels in the hypothalamus of the Tg4510 mice, but no differences in BMAL1 expression, which suggests a disruption in the timing of the negative arm of the clock in this tissue.
Tau pathology is evident in the SCN of Tg4510 mice
As the long free-running period suggests disruption of the master circadian clock in the hypothalamus, we set out to confirm the presence of tauopathy in this tissue as a potential cause for the behavioral and molecular circadian phenotypes. It has been observed that specific forms of phosphorylated tau (pTau) are associated with tau neuropathology. More specifically, phosphorylation of serine residues at 199-202 (pSer 199/202 ) and 396 (pSer 396 ) has been associated with the abnormal cleavage and folding of tau (Mondragon-Rodriguez et al., 2008; Hanger et al., 2009 ). Additionally, it has been observed that the phosphorylation pattern of tau might differ depending on the stage of tauopathy, and that phosphorylation of pSer 396 might be an early stage maker of tauopathy associated with AD (Mondragon-Rodriguez et al., 2014). Therefore, we performed Western blot analysis of pTau (pSer 199/202 , pSer 396 ) from hypothalamic tissue dissected from the 8 month old Tg4510 mice following the behavioral assessment of circadian rhythms as described above. As expected, we observed much higher levels of both pathological forms of pTau in the aged Tg4510 mice as compared to the non-transgenic control animals when combining all data for both time points (for 199/202, t(13) = 31.56, p b 0.0001; for 396, t(13) = 34.20, p b 0.0001; Fig. 3A and B) . Furthermore, although the levels show a trend towards a significant increase in pTau during the subjective morning, no significant circadian oscillation of either isoform was observed. Specifically, by two-way ANOVA, there was an effect of genotype for both 199/202 and 396 [F(1,14) = 19.84 for 199/202 and F = 16,388 for 396, both p b 0.01], but no effect of time of day and no interaction.
As previously mentioned, the SCN is the site of the master circadian oscillator. Therefore, it is reasonable to postulate that the long free-running period evident in the aged Tg4510 line might be due to the presence of tauopathy in the SCN. Although, it has recently been shown that the hypothalamus is a site of tauopathy in aged Tg4510 mice, the SCN specifically was not assessed (Joly-Amado et al., 2016) . Therefore, we examined the SCN for the presence of tauopathy by immunohistochemical analysis of both human wild type tau (hTau) and pTau (pSer 396 ) in 13 month old Tg and Ntg mice. Our results show the presence of both forms of tau in the SCN of the Tg4510 mice, but not in the Ntg littermate controls (Fig. 4) .
Disruption of the molecular circadian clock in the hippocampus of Tg4510 mice
As our results in the hypothalamus show an altered timing of the molecular clock in the presence of elevated pTau, we reasoned that this disruption might also be evident in the hippocampus -a region of the brain involved in memory and cognition, and a major site of tauopathy in the Tg4510 line . This brain region is also of interest as the hippocampus has a well-characterized autonomous molecular circadian clock (Wang et al., 2009 ).
Our first step was to confirm the presence of tauopathy in the hippocampus by assessing pTau pSer 199/202 and pSer 396 using the same methods as outlined for the hypothalamus. As expected, our results show high levels of both isoforms of pTau in the aged Tg4510 mice as compared to the non-transgenic controls [t (13) To determine the status of the molecular clock, we performed Western blot analysis of hippocampal tissue isolated from 8 month old freerunning Tg4510 and Ntg controls as described for the hypothalamus. As , but no interaction on hippocampal PER2. Specifically, PER2 was higher in the subjective evening for both genotypes. Therefore, we used two-tailed t-tests to compare between the subjective morning and evening within each genotype. We found a significant difference between PER2 levels at morning and evening in Ntg mice [t(7) = 5.82, p b 0.01], but no difference in the Tg4510 mice. This demonstrates an altered PER2 rhythm in the Tg4510 mice in the hippocampus in addition to the disruption observed in hypothalamus. (Fig. 6A and B) . However, there was only an effect of genotype on hippocampal BMAL1 [F(1,14) = 11.17, p b 0.01]. BMAL1 levels were higher overall, and in the subjective morning, in the Ntg mice ( Fig. 6A and C) . Taken as a whole, these data suggest a disruption in the timing of both the negative and positive arms of the molecular clock in the hippocampus of aged Tg4510 mice, and that there are tissue-specific differences in both the pTau profiles and in how the molecular clock is impacted by tauopathy in the Tg4510 mouse line.
Discussion
Our results show a long free-running period at an age when tauopathy is evident in transgenic Tg4510 mice, as well as an increase activity during "lights on" of the entrainment phase. Furthermore, immunohistochemical data show evidence of tauopathy in the SCN of Tg4510 mice. These data demonstrate that the core circadian clock in the SCN, which controls the timing of the sleep/wake cycle, is disrupted due to the presence of tauopathy. Additionally, the elevated activity during the sleep-phase (lights on in LD), and the shift towards a higher percentage of total activity occurring in the sleep-phase of the Tg4510 mice correspond to what has been reported in humans with FTD . Thus the Tg4510 line provides a good model to investigate how tauopathy impacts sleep and circadian rhythm biology. However, further studies are required to determine if this relationship is truly causal or correlative. Regardless of the underlying mechanism, these findings demonstrate for the first time that the presence of tauopathy is capable of circadian rhythm disruption. This suggests that in AD, where both β-amyloidosis and tauopathy are present, there may be an additive effect in disrupting circadian rhythms.
The abnormally short free-running period of the non-transgenic control mice was surprising (~23 h, Fig. 1 ). Additionally, several of the non-transgenic mice did not run consistently on the wheel, and had to be excluded from the data analysis. The mice used for this experiment are on a mixed genetic background that includes FVB, which could explain this phenomenon. In fact, it has been shown that mice on the FVB background have an unusual circadian profile of wheel-running activity (Pugh et al., 2004) .
In addition to disruption of the circadian clock at the behavioral level, we observed that the molecular clock is altered in the hypothalamus of aged Tg4510 mice. Specifically, we observed a decrease in PER2 rhythm in comparison to non-transgenic control tissue. This suggests that the timing of the negative arm of the molecular clock is altered in the hypothalamus of aged Tg4510 mice, which is to be expected given the long free-running period observed in the locomotor studies. However, we observed no change in BMAL1 between groups, which suggests the impact of tauopathy is primarily upon the negative arm of the clock in this tissue. It is important to note that there are multiple nuclei within the hypothalamus that have a functional molecular clock and that these nuclei may oscillate in phases different than the molecular clock in the SCN. Therefore, it is feasible that BMAL1 expression is altered in the SCN, but this was not observed as the entire hypothalamus was assessed.
Additionally we assessed the levels of phosphorylated tau in the hypothalamus to confirm the presence of tauopathy in the mice assessed in our locomotor studies. Here, we observed variable levels of phosphorylated tau at both time points assessed (Fig. 3A) and a trend towards an increase in both pSer 199/202 pSer 396 in the Tg4510 mice in the subjective morning (Fig. 3C) . The intra-timepoint variability is potentially due to the fact that the Tg4510 line relies on the CaMKII promoter to drive expression of the Tet activator. As CaMKII, and promoter-driven mutant tau, is expressed at much lower levels in the hypothalamus compared to the hippocampus and forebrain , it is somewhat surprising that tauopathy is evident in this tissue at all. We speculate that this is most likely due to either migration of soluble tau to the hypothalamus or to variability in tauopathy as a consequence of low mutant tau expression -or possibly a combination of both.
It is now widely appreciated that the circadian clock plays an important role in normal memory function (Gerstner and Yin, 2010) . Furthermore, it has been shown that there is a fully functional molecular clock in the hippocampus of mice (Wang et al., 2009) , and that a functional circadian clock is necessary for hippocampus-dependent learning (Ruby et al., 2008) . Memory is enhanced when the time of cognitive testing coincides with peak arousal, although the time of peak arousal varies among individual chronotypes (one's propensity to be an "early bird" versus a "night owl"; Folkard et al., 1983; Monk et al., 1983; Monk et al., 1984) . Because neurodegeneration occurs in the hippocampus of AD patients, it seems likely that the hippocampal molecular clock would be compromised. The Tg4510 mice display an age-dependent cognitive impairment due to tauopathy in the hippocampus (Ramsden et al., 2005) . As normal circadian clock function is important for memory and cognition, we tested whether the presence of tauopathy in the hippocampus of aged Tg4510 mice could disrupt the molecular clock. Our results show that this is indeed the case. Specifically, we observed that PER2 levels are significantly reduced in the subjective evening in the Tg4510 mice in comparison to the non-transgenic controls. These data show that the molecular clock in the hippocampus is altered in the presence of tauopathy. However, some important questions remain. Is the alteration of the molecular clock in the hippocampus secondary to a change in the timing of the molecular clockwork in the SCN? Is the presence of tauopathy alone in the hippocampus enough to disrupt the molecular circadian clock in this tissue? These questions are a current focus of our group to further our understanding as to how tauopathy impacts the circadian clock. Another interesting observation is that BMAL1 levels are reduced in aged Tg4510 hippocampal tissue in comparison to control tissue (Fig. 6B) . Recently, it has been shown that BMAL1 knockout mice show neurodegeneration due to reactive oxygen species (ROS)-induced astrogliosis (Musiek et al., 2013) . Thus, a reduction in BMAL1 levels may contribute to the neurodegeneration in the hippocampus of the Tg4510 mice.
We observed much more uniform levels of both pSer 199/202 pSer 396 in the aged Tg4510 hippocampus as compared to what was observed in the hypothalamus. Again, this is most likely due to the CaMKII promoter being expressed at a much higher level in the hippocampus. Surprisingly, we observed a time of day effect of pSer 396 in the Tg4510 mice (Fig. 5C ), where pSer 396 is increased in the subjective evening. These data combined with the trending time of day changes in the hypothalamus raise the possibility that pTau levels may change over the course of the day in a circadian manner. However, more work is needed to determine if pTau levels are indeed influenced by the circadian clock.
Here we demonstrate for the first time that the circadian clock is altered at both the behavioral and molecular levels in a mouse model of tauopathy. However, much more work is needed to determine the underlying mechanisms associated with these phenotypes. Furthermore, it will be important to determine if correcting this disruption can ameliorate the symptomology associated with neurodegenerative diseases such as AD and FTD.
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